Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
RESEARCH TOOLSreports
APLS Analyst Ratings
Moderate Buy
8 Buy
7 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
APLS Stock 12 Month Forecast
Average Price Target
$43.33
▲(58.14% Upside)
| Highest Price Target$78.00 | Average Price Target$43.33 | Lowest Price Target$26.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Mizuho Securities
Reiterated
02/14/25
H.C. Wainwright
Reiterated
02/13/25
Raymond James
Reiterated
02/13/25
Morgan Stanley
Reiterated
02/13/25
Oppenheimer
Reiterated
02/13/25
Jefferies
Reiterated
02/12/25
Wells Fargo
Reiterated
02/12/25
Piper Sandler
Reiterated
02/10/25
RBC Capital
Assigned
01/28/25
Bank of America Securities
Assigned
01/14/25
Stifel Nicolaus
―
Buy
―
Reiterated
01/13/25
Apellis Pharmaceuticals: Strong Sales, Strategic Growth, and Financial Resilience Justify Buy RatingWe are encouraged to see APLS announcing preliminary US net product revenues (excluding EU revenue from (+9.8% q/q) from Syfovre sales (Factset estimate $157mn) and $23mn from Empaveli—bringing the full-year total to $709mn with $611mn from Syfvore. After missing consensus the last two quarters, APLS looks on track to beat 4Q estimates on the back of strong Syfovre sales. To date, more than 510,000 injections have been administered with 94,000 vials (+6.2% q/q) distributed to physicians in 4Q24. With Syfovre net sales growing 120% y/y, APLS believes they are on the track to blockbuster status despite competitive headwinds from competitor, Izervay/Astellas.
TD Cowen
$60
Buy
118.98%
Upside
Reiterated
01/13/25
Positive Outlook and Buy Rating for Apellis Pharmaceuticals Driven by Strong Revenue Growth and Strategic DevelopmentsWe believe APLS is undervalued for both programs and remain at Buy.
J.P. Morgan
―
Buy
―
Reiterated
01/13/25
Positive Outlook for Apellis Pharmaceuticals Amid Strong Sales and Pipeline Advancements
Goldman Sachs
―
Hold
―
Downgraded
12/17/24
Goldman Sachs downgrades Apellis Pharmaceuticals (APLS) to a Hold
Scotiabank
$30
Hold
9.49%
Upside
Reiterated
11/20/24
Scotiabank Sticks to Their Hold Rating for Apellis Pharmaceuticals (APLS)
Best Analysts Covering Apellis Pharmaceuticals
Which Analyst Should I Follow If I Want to Buy APLS and Sell After:
1 Month
xxx
Success Rate
13/20 ratings generated profit
Average Return
+8.71%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 65.00% of your transactions generating a profit, with an average return of +8.71% per trade.
3 Months
xxx
Success Rate
15/24 ratings generated profit
Average Return
+4.82%
reiterated a xxx
rating 4 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 62.50% of your transactions generating a profit, with an average return of +4.82% per trade.
1 Year
Success Rate
15/29 ratings generated profit
Average Return
+8.36%
reiterated a buy rating last month
Copying Phil Nadeau's trades and holding each position for 1 Year would result in 51.72% of your transactions generating a profit, with an average return of +8.36% per trade.
2 Years
xxx
Success Rate
18/29 ratings generated profit
Average Return
+32.38%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 62.07% of your transactions generating a profit, with an average return of +32.38% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
APLS Analyst Recommendation Trends
Rating
Oct 24
Nov 24
Dec 24
Jan 25
Feb 25
Strong Buy
26
19
12
13
8
Buy
1
5
6
7
3
Hold
18
24
21
21
15
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
45
48
39
41
26
Each month's total comprises the sum of three months' worth of ratings.
APLS Financial Forecast
APLS Stock Forecast FAQ
What is APLS’s average 12-month price target, according to analysts?
Based on analyst ratings, Apellis Pharmaceuticals Inc’s 12-month average price target is $43.33.
What is APLS’s upside potential, based on the analysts’ average price target?
Apellis Pharmaceuticals Inc has 58.14% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is APLS a Buy, Sell or Hold?
Apellis Pharmaceuticals Inc has a consensus rating of Moderate Buy which is based on 8 buy ratings, 7 hold ratings and 0 sell ratings.
What is Apellis Pharmaceuticals Inc’s price target?
The average price target for Apellis Pharmaceuticals Inc is $43.33. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $78.00 ,the lowest forecast is $26.00. The average price target represents 58.14% Increase from the current price of $27.4.
The highest analyst price target is $78.00 ,the lowest forecast is $26.00. The average price target represents 58.14% Increase from the current price of $27.4.
What do analysts say about Apellis Pharmaceuticals Inc?
Apellis Pharmaceuticals Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of APLS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.